Fol. Biol. 2022, 68, 153-157
Circulating Cell-Free DNA Extraction from Liquid Biopsy for Cancer Research
As the number of cancer patients globally increases, a need for reliable biomarkers including circulating tumour DNA from liquid biopsy for diagnosis, prognosis and monitoring of the disease is rising. Currently, mainly tissue samples from biopsy are used, but there are certain limitations: firstly, it is an invasive technique, and secondly, in some cases it is almost impossible to obtain an acceptable tissue sample. This could be changed by using circulating cell-free DNA from liquid biopsy, which also gives the possibility of repeated examination. Here, we focus on the options of isolating circulating cell-free DNA from plasma samples using two isolation techniques: precision manual QIAamp Circulating Nucleic Acid Kit and automatic MagNA Pure Compact (MPC) using Nucleic Acid Isolation Kit I. Manual extraction gave significantly better yields of circulating tumour DNA (P < 0.05). This DNA also had less contaminants (organic compounds or proteins). DNA obtained by both tested methods of isolation is suitable for subsequent molecular genetic methods.
Keywords
biomarker, cancer, cell-free DNA, circulating tumour DNA, liquid biopsy, oncology, precision.
Funding
The study was supported by the European Regional Development Fund, projects BBMRI-CZ EF16_013/0001674, LM2018125, MH CZ DRO VFN 64165 and Cooperatio Laboratory Diagnostics.
References
Copyright
This is an open-access article distributed under the terms of the Creative Commons Attribution License.
